{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:53:30Z","timestamp":1794704010420,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00144"],"award-info":[{"award-number":["PI19\/00144"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert Koch institute","award":["1369-341"],"award-info":[{"award-number":["1369-341"]}]},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"crossref","award":["POCTEFA 2014-2020"],"award-info":[{"award-number":["POCTEFA 2014-2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002943","name":"Departament d'Innovaci\u00f3, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2018-BP-00129"],"award-info":[{"award-number":["2018-BP-00129"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2018-02532"],"award-info":[{"award-number":["2018-02532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-720931"],"award-info":[{"award-number":["ALFGBG-720931"]}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2017-00915"],"award-info":[{"award-number":["2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["RDAPB-201809-2016615"],"award-info":[{"award-number":["RDAPB-201809-2016615"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Alzheimer Foundation","award":["AF-742881"],"award-info":[{"award-number":["AF-742881"]}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2017-0243"],"award-info":[{"award-number":["FO2017-0243"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALF-agreement","award":["ALFGBG-715986"],"award-info":[{"award-number":["ALFGBG-715986"]}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2019-466-236"],"award-info":[{"award-number":["JPND2019-466-236"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood neurofilament light (Nfl) and total-tau (t-tau) have been described to be increased in several neurological conditions, including prion diseases and other neurodegenerative dementias. Here, we aim to determine the accuracy of plasma Nfl and t-tau in the differential diagnosis of neurodegenerative dementias and their potential value as prognostic markers of disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma Nfl and t-tau were measured in healthy controls (HC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970), non-neurodegenerative neurological disease with (NND-Dem,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) and without dementia syndrome (NND,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926), Alzheimer\u2019s disease (AD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944), Creutzfeldt-Jakob disease (CJD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200983), dementia with Lewy bodies\/Parkinson\u2019s disease with dementia (DLB\/PDD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935), frontotemporal dementia (FTD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), and vascular dementia (VaD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922). Biomarker diagnostic accuracies and cutoff points for the diagnosis of CJD were calculated, and associations between Nfl and t-tau concentrations with other fluid biomarkers, demographic, genetic, and clinical data in CJD cases were assessed. Additionally, the value of Nfl and t-tau predicting disease survival in CJD was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among diagnostic groups, highest plasma Nfl and t-tau concentrations were detected in CJD (fold changes of 38 and 18, respectively, compared to HC). Elevated t-tau was able to differentiate CJD from all other groups, whereas elevated Nfl concentrations were also detected in NND-Dem, AD, DLB\/PDD, FTD, and VaD compared to HC. Both biomarkers discriminated CJD from non-CJD dementias with an AUC of 0.93. In CJD, plasma t-tau, but not Nfl, was associated with\n                      <jats:italic>PRNP<\/jats:italic>\n                      codon 129 genotype and CJD subtype. Positive correlations were observed between plasma Nfl and t-tau concentrations, as well as between plasma and CSF concentrations of both biomarkers (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Nfl was increased in rapidly progressive AD (rpAD) compared to slow progressive AD (spAD) and associated to Mini-Mental State Examination results. However, Nfl displayed higher accuracy than t-tau discriminating CJD from rpAD and spAD. Finally, plasma t-tau, but not plasma Nfl, was significantly associated with disease duration, offering a moderate survival prediction capacity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma Nfl and t-tau are useful complementary biomarkers for the differential diagnosis of CJD. Additionally, plasma t-tau emerges as a potential prognostic marker of disease duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00815-6","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:12:04Z","timestamp":1618981924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Inga","family":"Zerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villar-Piqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Varges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidre","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Riggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"815_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.nicl.2016.02.019","volume":"11","author":"J Koikkalainen","year":"2016","unstructured":"Koikkalainen J, Rhodius-Meester H, Tolonen A, Barkhof F, Tijms B, Lemstra AW, Tong T, Guerrero R, Schuh A, Ledig C, Rueckert D, Soininen H, Remes AM, Waldemar G, Hasselbalch S, Mecocci P, van der Flier W, L\u00f6tj\u00f6nen J. Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage Clin. 2016;11:435\u201349. https:\/\/doi.org\/10.1016\/j.nicl.2016.02.019.","journal-title":"NeuroImage Clin"},{"key":"815_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.03.003","volume":"138\u2013140","author":"F Llorens","year":"2016","unstructured":"Llorens F, Schmitz M, Ferrer I, Zerr I. CSF biomarkers in neurodegenerative and vascular dementias. Prog Neurobiol. 2016;138\u2013140:36\u201353.","journal-title":"Prog Neurobiol"},{"key":"815_CR3","first-page":"1","volume":"2975","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Riederer P, O\u2019Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017;2975:1\u201385.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"815_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"815_CR5","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1212\/WNL.0000000000005860","volume":"91","author":"P Hermann","year":"2018","unstructured":"Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S, Treig J, Schulz-Schaeffer W, Cramm M, Schmitz M, Zerr I. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91(4):e331\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000005860.","journal-title":"Neurology."},{"issue":"10","key":"815_CR6","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1093\/brain\/awp191","volume":"132","author":"I Zerr","year":"2009","unstructured":"Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659\u201368. https:\/\/doi.org\/10.1093\/brain\/awp191.","journal-title":"Brain."},{"key":"815_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jalz.2017.12.008","volume":"4","author":"I Zerr","year":"2018","unstructured":"Zerr I, Schmitz M, Karch A, Villar-Piqu\u00e9 A, Kanata E, Golanska E, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;4:751\u201363.","journal-title":"Alzheimers Dement"},{"issue":"21","key":"815_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945\u201353. https:\/\/doi.org\/10.1212\/WNL.0000000000001015.","journal-title":"Neurology."},{"issue":"1","key":"815_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.24052","volume":"75","author":"CS Scherling","year":"2014","unstructured":"Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J Jr, Boxer AL. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116\u201326. https:\/\/doi.org\/10.1002\/ana.24052.","journal-title":"Ann Neurol"},{"issue":"1","key":"815_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.dadm.2016.05.005","volume":"3","author":"U Andreasson","year":"2016","unstructured":"Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst). 2016;3(1):98\u2013102. https:\/\/doi.org\/10.1016\/j.dadm.2016.05.005.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"815_CR11","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P, Giese A, Kuhle J, Slivarichova D, Zetterberg H, Otto M. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6(1):38737. https:\/\/doi.org\/10.1038\/srep38737.","journal-title":"Sci Rep"},{"issue":"13","key":"815_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Druyeh R, Cardoso MJ, Ourselin S, Nicholas JM, Norgren N, Mead S, Andreasson U, Blennow K, Schott JM, Fox NC, Warren JD, Zetterberg H. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329\u201336. https:\/\/doi.org\/10.1212\/WNL.0000000000003154.","journal-title":"Neurology."},{"issue":"3","key":"815_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival-Alwyn J, Schultz A, Properzi M, Johnson K, Selkoe DJ, Sperling RA, Patel P, Zetterberg H, Galasko D, Schott JM, Walsh DM. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(3):487\u201396. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.010.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"815_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V, Regelsberger G, Lutz MI, Danics K, Keller E, Zetterberg H, Blennow K. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017;24(11):1326\u201377. https:\/\/doi.org\/10.1111\/ene.13389.","journal-title":"Eur J Neurol"},{"issue":"9","key":"815_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/jnnp-2017-317793","volume":"89","author":"AGB Thompson","year":"2018","unstructured":"Thompson AGB, Luk C, Heslegrave AJ, Zetterberg H, Mead SH, Collinge J, Jackson GS. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry. 2018;89(9):955\u201361. https:\/\/doi.org\/10.1136\/jnnp-2017-317793.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"815_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/jnnp-2017-317260","volume":"89","author":"MS Foiani","year":"2018","unstructured":"Foiani MS, Woollacott IOC, Heller C, Bocchetta M, Heslegrave A, Dick KM, Russell LL, Marshall CR, Mead S, Schott JM, Fox NC, Warren JD, Zetterberg H, Rohrer JD. Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018;89(8):804\u20137. https:\/\/doi.org\/10.1136\/jnnp-2017-317260.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"815_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"issue":"1","key":"815_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058.","journal-title":"Neurology."},{"issue":"12","key":"815_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22(12):1689\u2013707. https:\/\/doi.org\/10.1002\/mds.21507.","journal-title":"Mov Disord"},{"issue":"5","key":"815_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology."},{"issue":"6","key":"815_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, M\u00fcller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, for the Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"issue":"9","key":"815_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15.","journal-title":"Neurology."},{"issue":"9","key":"815_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain."},{"issue":"2","key":"815_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250\u201360. https:\/\/doi.org\/10.1212\/WNL.43.2.250.","journal-title":"Neurology."},{"issue":"1","key":"815_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","volume":"16","author":"A Villar-Piqu\u00e9","year":"2019","unstructured":"Villar-Piqu\u00e9 A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, Ferrer I, Riggert J, Llorens F, Zerr I. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16(1):145. https:\/\/doi.org\/10.1186\/s12974-019-1531-3.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"815_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/nan.12573","volume":"46","author":"F Llorens","year":"2020","unstructured":"Llorens F, Villar-Piqu\u00e9 A, Schmitz M, Diaz-Lucena D, Wohnlage M, Hermann P, et al. Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases. Neuropathol Appl Neurobiol. 2020;46(3):240\u201354. https:\/\/doi.org\/10.1111\/nan.12573.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"815_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ana.410430109","volume":"43","author":"I Zerr","year":"1998","unstructured":"Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998;43(1):32\u201340. https:\/\/doi.org\/10.1002\/ana.410430109.","journal-title":"Ann Neurol"},{"key":"815_CR28","volume-title":"Multiple comparisons using R. Multiple comparisons using R","author":"F Bretz","year":"2010","unstructured":"Bretz F, Hothorn T, Westfall P. Multiple comparisons using R. Multiple comparisons using R. Boca Raton: CRC Press; 2010."},{"issue":"1","key":"815_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, M\u00fcller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics"},{"key":"815_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000. https:\/\/doi.org\/10.1007\/978-1-4757-3294-8."},{"issue":"3","key":"815_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/2986270","volume":"43","author":"P Royston","year":"1994","unstructured":"Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat. 1994;43(3):429. https:\/\/doi.org\/10.2307\/2986270.","journal-title":"Appl Stat"},{"issue":"2","key":"815_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.32614\/RJ-2017-046","volume":"9","author":"P Breheny","year":"2017","unstructured":"Breheny P, Burchett W. Visualization of regression models using visreg. R J. 2017;9(2):56\u201371. https:\/\/doi.org\/10.32614\/RJ-2017-046.","journal-title":"R J"},{"issue":"10","key":"815_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737175.2018.1519397","volume":"18","author":"I Zerr","year":"2018","unstructured":"Zerr I, Hermann P. Diagnostic challenges in rapidly progressive dementia. Expert Rev Neurother. 2018;18(10):761\u201372. https:\/\/doi.org\/10.1080\/14737175.2018.1519397.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"815_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/bmb\/66.1.213","volume":"66","author":"P Gambetti","year":"2003","unstructured":"Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66(1):213\u201339. https:\/\/doi.org\/10.1093\/bmb\/66.1.213.","journal-title":"Br Med Bull"},{"issue":"5","key":"815_CR35","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.neurobiolaging.2015.01.021","volume":"36","author":"A Karch","year":"2015","unstructured":"Karch A, Hermann P, Ponto C, Schmitz M, Arora A, Zafar S, Llorens F, M\u00fcller-Heine A, Zerr I. Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease. Neurobiol Aging. 2015;36(5):1964\u20138. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.01.021.","journal-title":"Neurobiol Aging"},{"key":"815_CR36","volume-title":"Package \u201csurvival\u201d","author":"T Therneau","year":"2020","unstructured":"Therneau T, Atkinson E. Concordance. In: Package \u201csurvival\u201d; 2020. Cran.r-project.org. https:\/\/cran.r-project.org\/web\/packages\/survival\/survival.pdf."},{"issue":"11","key":"815_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/jnnp-2020-323826","volume":"91","author":"SA Rumeileh","year":"2020","unstructured":"Rumeileh SA, Baiardi S, Ladogana A, Zenesini C, Stella AB, Poleggi A, et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J Neurol Neurosurg Psychiatry. 2020;91(11):1181\u20138. https:\/\/doi.org\/10.1136\/jnnp-2020-323826.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"815_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1083\/jcb.74.1.241","volume":"74","author":"WW Schlaepfer","year":"1977","unstructured":"Schlaepfer WW, Lynch RG. Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol. 1977;74(1):241\u201350. https:\/\/doi.org\/10.1083\/jcb.74.1.241.","journal-title":"J Cell Biol"},{"key":"815_CR39","doi-asserted-by":"publisher","first-page":"1922.e7","DOI":"10.1016\/j.neurobiolaging.2013.01.017","volume":"34","author":"E Majounie","year":"2013","unstructured":"Majounie E, Cross W, Newsway V, Dillman A, Vandrovcova J, Morris CM, et al. Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging. 2013;34:1922.e7\u20131922.e12.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"815_CR40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ana.410390613","volume":"39","author":"P Parchi","year":"1996","unstructured":"Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AAF, Trojanowski JQ, Petersen RB, Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39(6):767\u201378. https:\/\/doi.org\/10.1002\/ana.410390613.","journal-title":"Ann Neurol"},{"key":"815_CR41","volume-title":"Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases","author":"A Thompson","year":"2020","unstructured":"Thompson A, Anastasiadis P, Druyeh R, Whitworth I, Nayak A, Nihat A, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. 2020. Preprint at: https:\/\/www.medrxiv.org\/content\/early\/2020\/07\/29\/2020.07.27.20157594."},{"key":"815_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/JAD-179926","volume":"64","author":"H Zetterberg","year":"2018","unstructured":"Zetterberg H, Blennow K. From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer\u2019s disease. J Alzheimers Dis. 2018;64:271\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"17","key":"815_CR43","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K, ADNI Investigators. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000003246.","journal-title":"Neurology."},{"issue":"9","key":"815_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, Machulda MM, Roberts RO, Jack CR Jr, Petersen RC, Dage JL. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 2017;74(9):1073\u201380. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1359.","journal-title":"JAMA Neurol"},{"issue":"5","key":"815_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase MP, Beiser AS, Himali JJ, Satizabal CL, Aparicio HJ, Decarli C, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76(5):598\u2013606. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4666.","journal-title":"JAMA Neurol."},{"issue":"2","key":"815_CR46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383. https:\/\/doi.org\/10.1038\/s41591-018-0304-3.","journal-title":"Nat Med"},{"issue":"7","key":"815_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765.","journal-title":"JAMA Neurol."},{"issue":"3","key":"815_CR48","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C Jr, Petersen RC, Kern S. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252\u201360. https:\/\/doi.org\/10.1212\/WNL.0000000000007767.","journal-title":"Neurology."},{"issue":"4","key":"815_CR49","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, Wermeling P, Sedaghat S, Ikram MK, Waziry R, Koudstaal W, Klap J, Kostense S, Hofman A, Anderson R, Goudsmit J, Ikram MA. Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study. Brain. 2020;143(4):1220\u201332. https:\/\/doi.org\/10.1093\/brain\/awaa054.","journal-title":"Brain."},{"issue":"5","key":"815_CR50","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.21873\/invivo.12075","volume":"34","author":"J Onatsu","year":"2020","unstructured":"Onatsu J, Vanninen R, J\u00e4k\u00e4l\u00e4p, Mustonen P, Pulkki K, Korhonen M, et al. Tau, S100B and NSE as blood biomarkers in acute cerebrovascular events. Vivo. 2020;34(5):2577\u201386. https:\/\/doi.org\/10.21873\/invivo.12075.","journal-title":"Vivo."},{"issue":"10","key":"815_CR51","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/brain\/awh249","volume":"127","author":"M Pocchiari","year":"2004","unstructured":"Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127(10):2348\u201359. https:\/\/doi.org\/10.1093\/brain\/awh249.","journal-title":"Brain."},{"issue":"5","key":"815_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","volume":"12","author":"F Llorens","year":"2016","unstructured":"Llorens F, R\u00fcbsamen N, Hermann P, Schmitz M, Villar-Piqu\u00e9 A, Goebel S, et al. A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease. Alzheimers Dement. 2016;12(5):577\u201389. https:\/\/doi.org\/10.1016\/j.jalz.2015.10.009.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"815_CR53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2019.1071","volume":"76","author":"AM Staffaroni","year":"2019","unstructured":"Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orr\u00fa CD, Caughey B, Allen IE, Kramer JH, Rosen HJ, Blennow K, Zetterberg H, Geschwind MD. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol. 2019;76(8):969\u201377. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1071.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:53:21Z","timestamp":1618984401000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00815-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and was approved by all local Ethics committees (reference numbers 11\/11\/93, 5\/09\/08, 9\/06\/08, 19\/11\/09 University Medical School, G\u00f6ttingen, Germany). All study participants or their legal guardians provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}